REFRACTORY/RELAPSED.HODGKIN.LYMPHOMA:.THE.PROFILE.OF.PATIENTS.
REFERRED.TO.AUTOLOGOUS.STEM.CELL.TRANSPLANTATION..
.
Maria% Eduarda% Couto1,2,% Carlos% Pinho% Vaz2,% Gil% Bras2,% Luis% Leite2,% Rosa% Branca2,% Susana% Roncon3%and%
António%Campos%Júnior2%
%
(1)Onco(hematology1Service,1Instituto1Português1de1Oncologia1do1Porto,1F.G.,1E.P.E.,1Porto,1Portugal,1
(2)Bone1Marrow1Transplant1Service,1Instituto1Portugues1de1Oncologia1do1Porto,1E.P.E,1Porto,1Portugal,1
(3)Cellular1Therapy1Service,1Instituto1Portugues1de1Oncologia1do1Porto,1E.P.E,1Porto,1Portugal1
%
Refractory/relapsed% Hodgkin% Lymphoma% (R/R% HL)% has% few% therapeutic% options% apart% the%
stem% cell% transplant% (SCT).% Most% of% the% patients% are% young,% but% all% were% unresponsive% to%
several%treatment%lines%(most%of%them%with%relevant%toxicity).%
We% performed% a% retrospective% analysis% about% the% profile% of% all% patients% with% R/R% HL% who%
were% submitted% to% autologous% SCT% along% 6% years% (2013U2018)% in% one% center.% The% Kaplan–
Meier%curve%was%used%to%estimate%the%overall%(OS)%and%progressionUfree%survival%(PFS)%after%
the%first%line%therapy.%
We%analyzed%53%patients%(median%age%28%years%12U55%at%diagnosis%time%and%30%years%13U59%
at% the% moment% of% autologous% SCT;% 64.2%% males;% 41.5%% IPS% 0U1).% All% cases% were% diagnosed%
with%HL%between%1983%and%2017.%The%escleroUnodular%type%was%found%in%86.8%%of%the%cases;%
35.8%% were% in% stage% II% of% disease,% 24.5%% in% stage% III% and% 39.6%% in% stage% IV.% The% median%
number% of% previous% therapy% lines% was% 3% 2U6.% In% the% first% line% (n=53),% 84.9%% were% treated%
with%ABVD%(+/U%radiotherapy)%and%5.7%%with%BEACOPP.%The%median%progression%free%survival%
after%first%line%therapy%was%4%months%0U252%(IC%95%%0U8).%In%the%second%line%(n=53),%58.5%%
did%(R)ICE%(+/U%radiotherapy)%and%20.8%%did%ESHAP%(+/U%radiotherapy).%In%the%third%line%(n=28),%
67.9%%did%GVD%and%10.7%%did%Brentuximab.%In%the%fourth%line%(n=5),%40%%did%GVD,%20%%did%
ESHAP,% 20%% did% Brentuximab% and% other% 20%% did% IGEV.% In% the% fifth% line% (n=3),% 33%% did%
Vinblastine,%33%%did%Bendamustine%and%33%%did%Nivolumab.%Only%one%patient%was%submitted%
to% a% sixth% line% therapy% with% Nivolumab.% All% these% cases% proceeded% to% autoSCT% and% 88.7%%
achieved%a%response%(complete%in%84.9%).%
Six%patients%died%until%the%end%of%the%study%(all%of%them%in%disease%progression).%The%median%
followUup%time%was%361.8%months%295U428,%with%one%loss%of%followUup%after%the%autologous%
SCT.%Seven%patients%did%allogenic%SCT%posteriorly.%
R/R%HL%have%few%therapeutic%options%available%apart%the%SCT.%Most%patients%were%exposed%to%
several%treatment%lines%before%this%procedure,%becoming%progressively%less%fit%and%with%more%
comorbidities%due%to%toxicity.%More%effective%and%less%toxic%therapeutic%options%are%needed%
for%these%patients%(novel%agents)%that%can%be%used%before%the%SCT.%
% %
SCIENTIFIC PROGRAMME
SESSION I
HODGKIN’S DISEASE
DEBATE I
IS THERE STILL A ROLE
FOR COMBINED MODALITY
THERAPY FOR EARLY
STAGE CHL?
SESSION II
T-CELL LYMPHOMA
ROUNDTABLE I
FUTURE DIRECTIONS IN
T-CELL LYMPHOMA
SESSION III
FOLLICULAR LYMPHOMA
DEBATE II
CAN WE AVOID
CHEMOTHERAPY IN
THE MANAGEMENT OF
FOLLICULAR LYMPHOMA?
SESSION IV
RARE LYMPHOMAS –
MARGINAL ZONE
LYMPHOMA AND
WALDENSTRÖM M
ACROGLOBULINEMIA
ROUNDTABLE II – WHERE
TO GO IN RARE B-CELL
LYMPHOMAS
SESSION V
MANTLE CELL LYMPHOMA
SESSION VI
DIFFUSE LARGE B-CELL
LYMPHOMA
DEBATE III
DO WE STILL NEED ASCT
IN MCL?
SESSION VII
NOVEL THER APEUTIC
CONCEPTS IN B-CELL
LYMPHOMAS
SELECTED ABSTRACTS
FOR AN ORAL
PRESENTATION
SELECTED ABSTRACTS
FOR A POSTER
PRESENTATION
DISCLOSURES